NovImmune raised €49M in a Series D+ round in Feb 2014. The company is based in Plan-les-Ouates, Switzerland. Investors in the round: Rosetta Capital. Data as of 7 Aug 2026.
No source on record — unverified.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
